6550--Blood Bank Reagents

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

257-NETWORK CONTRACT OFFICE 17 (36C257)

Contract Value

Not provided

Codes & Classification
Solicitation Number

36C25727Q0065

NAICS

325413 - In-Vitro Diagnostic Substance Manufacturing

Classification Code

-

Additional Details
Set Aside

None

Place of Performance

Dallas, Texas, UNITED STATES

SourceSAM
Documents1
The Department of Veterans Affairs (VA), through its North Texas Health Care System (VANTHCS) located in Dallas, Texas, is conducting market research to identify qualified vendors capable of supplying blood bank reagents for use in its Transfusion Medicine Unit within the Pathology and Laboratory Medicine Service (P&LMS). This notice, issued under procurement identifier 36C25727Q0065, is a Sources Sought announcement and does not constitute a solicitation for bids, proposals, or quotes. Its primary purpose is to gather information from potential suppliers to inform the Government’s acquisition strategy for this requirement. The scope of this procurement centers on the provision of specialized blood bank reagents essential for manual blood typing and serum antibody detection and identification. These reagents are critical for cross-matching blood in transfusion procedures, directly supporting patient care within the VA North Texas Health Care System. The anticipated deliverables include a range of ALBAcyte products, specifically: - ALBAcyte A1 Cells (Z401U) – 52 units annually - ALBAcyte A2 Cells (Z406U) – 13 units annually - ALBAcyte B Cells (Z411U) – 52 units annually - ALBAcyte IgG Sensitized Cells (weak, Z4411U-1) – 26 units annually - ALBAcyte Antibody ID Panel (16-cell, Z473U) – 7 units annually - ALBAcyte C3 Coated Red Blood Cells (Z482U) – 13 units annually The period of performance is structured as a base year from May 1, 2027, through April 30, 2028, with four additional one-year option periods extending through April 30, 2032. All products will be delivered to the VA North Texas Health Care System at 4500 S. Lancaster Rd., Dallas, TX 75216. Key requirements for prospective vendors include: - FDA approval for all supplied reagents, with supporting documentation required. - A defined quality plan and assurance of adequate supply availability. - Capability to provide all shipping and freight on an FOB Destination basis, unless otherwise negotiated and communicated prior to award. - Timely delivery of reagents as specified in each order, utilizing appropriate shipping containers to maintain product integrity. The anticipated North American Industry Classification System (NAICS) code for this procurement is 325413 (In-Vitro Diagnostic Substance Manufacturing), with a corresponding Product Service Code (PSC) of 6550 (In-Vitro Diagnostic Substances, Reagents, Test Kits and Sets). The contracting activity is managed by the 257-Network Contract Office 17, a federal office under the Department of Veterans Affairs. Interested vendors are invited to submit a capability statement, including the place of manufacture for each reagent, via email in PDF or Word format to Teresa Arzola at [email protected] by 9:00 AM Central Standard Time on November 5, 2026. All communications must reference the subject line: “Sources Sought Blood Bank Reagents VA North Texas HCS.” No telephone inquiries will be accepted. It is important to note that this Sources Sought notice is for informational and planning purposes only. Submission of a capability statement is voluntary and does not obligate the Government to issue a solicitation or award a contract. The information collected will be used solely to assess market capability and to determine the most appropriate acquisition strategy, which may include small business set-asides or unrestricted competition. Contractors evaluating this opportunity should ensure they meet the regulatory, quality, and logistical requirements outlined, and be prepared to demonstrate their ability to reliably supply the specified blood bank reagents over the multi-year contract period.